tucotuzumab celmoleukin + cyclophosphamide

Tucotuzumab celmoleukin + cyclophosphamide is a combination investigational immunotherapeutic regimen. Tucotuzumab celmoleukin (EMD 273066, huKS-IL2) is a recombinant immunocytokine, consisting of a humanized monoclonal antibody (tucotuzumab, huKS) targeting the epithelial cell adhesion molecule (EpCAM) fused to interleukin-2 (IL-2)[7][9]. This fusion protein is designed to directly stimulate immune cell activity (T and NK cells) at tumor sites via IL-2 and target EpCAM-expressing tumors, enhancing antibody-dependent cellular cytotoxicity and immune activation. Cyclophosphamide is a cytotoxic alkylating agent that is used at low doses in combination regimens to provide immunomodulatory effects by depleting regulatory T cells and promoting tumor immunity, as well as to directly kill proliferating tumor cells. This combination has been tested in early-phase clinical trials in patients with EpCAM-positive advanced solid tumors[4]. Primary indications under investigation include prostate cancer, ovarian cancer, and other EpCAM-positive advanced solid tumors[4][8]. Tucotuzumab celmoleukin was originally developed by EMD Serono (a division of Merck KGaA).

Brand names

tucotuzumab celmoleukin

Other names

EMD 273066 + cyclophosphamidehuKS-IL2 + cyclophosphamide